European Medicines Agency approves Moderna's mRNA flu vaccine with strong efficacy in older adults. US FDA initially declines to review the same vaccine despite positive clinical trial data. Moderna's ...

GSK (NYSE:GSK) respiratory, immunology and inflammation R&D head Kaivan Khavandi said the company is positioning several late-stage programs around clear unmet need and what he described as better ...

Arbutus Biopharma has entered its 2026 fiscal year on a strengthened financial footing, having significantly reduced its net ...

Moderna is scaling its mRNA production capabilities and hiring specialized engineers, as its stock surges over 75% YTD amid a shift beyond COVID-19 vaccines.

Moderna (MRNA +3.02%) is best known for its coronavirus vaccine, a product that generated more than $18 billion in revenue at ...

On March 19, 2026, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a $35 ...

The S&P 500 Index and its top ETFs, such as Vanguard’s VOO and State Street’s SPY, have declined sharply in the past few days ...

U.S. large-cap healthcare stocks have delivered modest year-to-date gains in 2026, holding steady into March amid its ...

Pfizer (PFE +0.95%) and Moderna (MRNA +0.07%) were both leaders in the coronavirus vaccine market. However, as sales of these ...

Generate Biomedicines IPO highlights AI-driven drug discovery, strong backing, promising pipeline, and investor confidence ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines ...